Semaglutide

Semaglutide is an acylated GLP-1 analog with a half-life of approximately one week, achieved through albumin binding and DPP-4 resistance. It is the most extensively studied peptide in this library, with completed cardiovascular outcome studies.

Agonism at the GLP-1 receptor increases glucose-dependent insulin secretion, suppresses inappropriate glucagon release, slows gastric emptying, and acts on circuits in the hypothalamic arcuate nucleus to reduce appetite and energy intake.

Store the sealed lyophilized vial at 2-8 °C, protected from light; brief exposure to room temperature during shipping is generally tolerated. Refrigerate after reconstitution at 2-8 °C and use within the period supported by stability data for the substance (typically 2-4 weeks). Avoid repeated freeze-thaw cycles: each cycle increases the risk of aggregation and hydrolysis of the peptide bond. Do not shake the vial; swirl gently and direct the liquid stream against the glass wall rather than at the powder cake.

• Sealed lyophilized vial, stored as supplied
• Bacteriostatic water (0.9% benzyl alcohol) for reconstitution
• Insulin syringes (29-31G, 0.5 mL / 100 units)
• Reconstitution syringe (1-3 mL, 21-23G needle)
• 70% isopropyl alcohol swabs
• Sharps container for used needles
• Labels and a logbook for batch, date and volume

The STEP and SUSTAIN programs reported a mean weight reduction of approximately 15% and a significant HbA1c reduction, respectively; SELECT reported fewer major adverse cardiovascular events in a non-diabetic population with overweight. Common adverse effects are gastrointestinal. Label warnings include pancreatitis, gallbladder disease, and thyroid C-cell tumors in rodents.

Wash your hands, then disinfect the vial septum and the injection site with 70% isopropyl alcohol and allow both to air dry. Draw up the intended volume, remove air bubbles and pinch a subcutaneous skin fold. Insert at a 45-90° angle depending on fat thickness, aspiration is not required for subcutaneous administration, and inject slowly. Withdraw the needle, apply light pressure and discard the needle in a sharps container. Rotate injection sites systematically (abdominal quadrants, flanks, thighs) to prevent lipohypertrophy and local irritation.

Peptide research protocols are studied against a background of adequate protein intake (approximately 1.6-2.2 g/kg/day in the training literature), consistent sleep of 7-9 hours, and controlled training load. Sleep deprivation and chronic psychological stress both dampen growth hormone pulsatility and disrupt tissue remodeling, complicating the interpretation of any observed effect. Alcohol, smoking and large caloric deficits are likewise documented modifiers of recovery outcomes.

1. Wilding J.P.H. et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med, 2021.
2. Marso S.P. et al. Semaglutide and cardiovascular outcomes (SUSTAIN-6). N Engl J Med, 2016.
3. Lincoff A.M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med, 2023.